Evidence map›Paper›PMID 41281752›Full record

ArticleInternational journal of biological sciences2025

CCL2 supports human hepatocytes long-term expansion for bioartificial liver therapy to relieve acute liver failure and extrahepatic complications.

Zibin Zhan, Xuewen Liu, Min Zeng, Zehua Li, Yue Zhang, Xueyan Qiao, Xinming Li, Xianfeng Xia, Kunhao Bai, Fanhong Zeng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zibin ZhanDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xuewen LiuDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Min ZengDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zehua LiDepartment of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Yue ZhangThe Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.
Xueyan QiaoDepartment of Ultrasound, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xinming LiDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xianfeng XiaDepartment of Surgery and State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.
Kunhao BaiDepartment of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Fanhong ZengDepartment of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
Yi GaoDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jun WengDepartment of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lack of expandable human hepatocytes in vitro hampers the clinical application of the bioartificial liver. Previous studies have shown that chemical cocktails containing growth factors can support long-term expansion of hepatocytes through dedifferentiation. Here, it is revealed that chemokine (C-C motif) ligand 2 (CCL2) is a key factor in liver regeneration. CCL2 could promote the long-term expansion (over 30 passages) of human primary hepatocytes and enhancing their proliferative efficiency. Subsequently, CCL2-mediated proliferation of hepatocytes can effectively expand in vitro, and repopulate the liver of Fah

Indexed as

Chemokine CCL2HepatocytesLiver, ArtificialLiver Failure, AcuteAnimalsCell ProliferationCells, CulturedHumansLiver RegenerationMaleMiceMice, Inbred C57BLSwineChemokine CCL2acute liver failurebioartificial liverCCL2hepatic encephalopathyhepatocyte proliferation

Identifiers

PMID41281752
PMCPMC12631109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.